|Bid||50.69 x 900|
|Ask||50.70 x 1300|
|Day's Range||50.47 - 50.94|
|52 Week Range||37.38 - 51.13|
|PE Ratio (TTM)||52.78|
|Dividend & Yield||1.06 (2.08%)|
|1y Target Est||N/A|
Abiomed is primarily focused on the growth opportunity in the protected PCI area, a procedure that is applicable for patients with coronary artery disease.
To improve clinical outcomes and increase the number of patients treated in the United States using Impella, Abiomed has launched the Abiomed Impella Quality Program.
Johnson & Johnson (JNJ) reported Medical Devices segment sales of ~$6.7 billion in 2Q17, compared with $6.4 billion in 2Q16.